ESC Congress 2017 In Review -- Main Edition - 2

Dear Practitioner,
We are pleased to share with you highlights from the European Society of Cardiology (ESC) Congress 2017
held in Barcelona, Spain.
The featured article provides a topline summary of the new guidelines released by the ESC during the
Congress. It covers the management of acute myocardial infarction (MI) in patients presenting with ST-segment elevation, the diagnosis and treatment of peripheral arterial diseases (PAD), the management of valvular heart disease, and a focused update on dual antiplatelet therapy in patients.
A number of highly anticipated and potentially practice-changing clinical trials were presented at ESC
Congress 2017, including the results from the COMPASS, CANTOS, and ORION-1 studies. COMPASS extended
the results from ATLAS TIMI-51 demonstrating that rivaroxaban 2.5 mg BID plus aspirin was superior to
aspirin alone for prevention of cardiovascular (CV) death, stroke, or MI in patients with stable CAD or PAD.
The CANTOS study of canakinumab, a human monoclonal antibody directed against IL-1β, in patients with
CAD and residual inflammatory risk was the first trial to target inflammation to reduce CV events. The results showed that canakinumab significantly reduced the risk of CV events when added to a background of
optimal medical therapy without affecting lipids, they also help to validate the hypothesis of a connection
between inflammation and atherosclerosis. Furthermore, a reduction in fatal lung cancers was an added
benefit although tempered somewhat by an increase in deaths due to infection. The ORION-1 study showed
that inclisiran, an oligonucleotide that interferes with the mRNA encoding for the PCSK9 protein, delivered
at a dose of 300 mg subcutaneously twice per year, lowered low-density lipoprotein cholesterol (LDL-C) by
approximately 50% for up to 1 year in patients with high CV risk and elevated LDL-C.
In addition to the results from Hot Line session clinical trials and registry updates, you will also find information on selected areas of CV medicine including cholesterol-lowering therapy for primary and secondary
prevention, a look at future therapies for heart failure, and the prevention and management of acute stroke.
We hope that you find the articles and practical perspectives that are contained in the pages of this issue
of ESC Congress 2017 in Review helpful in integrating this new information into your clinical practice.

Robert P. Giugliano, MD, SM

Marc P. Bonaca, MD, MPH

Jacob A. Udell, MD, MPH

Nihar R. Desai, MD, MPH

Matthew Cavender, MD, MPH

Erin A. Bohula May, MD, PhD

Giulia Magnani, MD, PhD

Carlos Aguiar, MD, FESC

Jan Steffel, MD, FESC, FHRS

Staff Physician Cardiovascular Division
Brigham and Women's Hospital
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts, USA

Associate Physician Cardiovascular Division
Yale-New Haven Hospital
Assistant Professor Medicine
Yale School of Medicine
New Haven, Connecticut, USA

Consultant, Department of Cardiology
University Hospital Zurich
Zurich, Switzerland

2

October 2017

Physician Vascular Section
Cardiovascular Division
Brigham and Women's Hospital
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts, USA

Assistant Professor of Medicine
University of North Carolina
Chapel Hill, North Carolina, USA

Department of Cardiology
Hospital de Santa Cruz
Carnaxide, Portugal

Physician Cardiovascular Division
Women's College Hospital
Toronto General Hospital
Assistant Professor of Medicine
University of Toronto
Toronto, Ontario, Canada

Associate Physician Cardiovascular Division
Brigham and Women's Hospital
Instructor in Medicine
Harvard Medical School
Boston, Massachusetts, USA

Co-Head, Division of Electrophysiology and
Devices
Senior Consultant, Department of Cardiology
University Heart Center Zurich
University Hospital Zurich
Zurich, Switzerland

www.escardio.org/ESCcongressinreview
http://www.escardio.org/ESCcongressinreview
Table of Contents for the Digital Edition of ESC Congress 2017 In Review -- Main Edition
